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Abstract 
Acyclic nucleoside phosphonates (ANPs) that contain a 6-oxopurine base are good inhibitors 
of the human and Plasmodium falciparum 6-oxopurine phosphoribosyltransferases (PRTs), 
key enzymes of the purine salvage pathway. Chemical modifications, based on the crystal 
structures of several inhibitors in complex with the human PRTase, led to the design of a new 
class of inhibitors – the aza-ANPs. Because of the negative charges of the phosphonic acid 
moiety, their ability to cross cell membranes is, however, limited. Thus, phosphoramidate 
prodrugs of the aza-ANPs were prepared to improve permeability. These prodrugs arrest 
parasitemia with IC50 values in the micromolar range against Plasmodium falciparum-infected 
erythrocyte cultures (both chloroquine-sensitive and chloroquine-resistant Pf strains). The 
prodrugs exhibit low cytotoxicity in several human cell lines. Thus, they fulfill two essential 
criteria to qualify them as promising antimalarial drug leads. 
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Introduction 
Malaria remains one of the most important infectious diseases in the world today, with 
~48% of the human population living in areas of risk.
1
 The two principal protozoan parasites 
that cause human malaria are Plasmodium falciparum (Pf) and Plasmodium vivax (Pv). The 
frontline defence against malaria has been chemotherapeutic drugs (i.e. chloroquine, quinine, 
artemisinin-combination therapies - ACTs). However, because of developing resistance to 
first-line treatment drugs (i.e. ACTs) in Southeast Asia, there is an urgent need to discover 
new targets and drugs that are capable of combating this disease.
2,3
 
Hypoxanthine-guanine-(xanthine) phosphoribosyltransferase [HG(X)PRT] is a 
recognized target for drugs aimed at malaria.
4,5
 This is because HG(X)PRT is a key enzyme 
of the purine salvage pathway where it synthesises the nucleoside monophosphates required 
for DNA/RNA production. Mammals are able to synthesize the purine ring de novo and, 
hence, do not have an absolute reliance on the salvage pathway. However, parasites of the 
genus Plasmodium depend entirely on the transport of preformed bases from the host cell and, 
thus, rely on the activity of HG(X)PRT for both survival and replication.
6
 This enzyme 
catalyses the formation of the 6-oxopurine nucleoside monophosphates (IMP, GMP or XMP) 
from a purine base (hypoxanthine, guanine or xanthine, respectively) and 5-phospho-α-D-
ribosyl-1-pyrophosphate (PRib-PP) (Fig. 1A).
7
  
 
Fig. 1. A) The reaction catalysed by HG(X)PRT. R = -H (hypoxanthine); -NH2 (guanine); -
OH (xanthine). B) General structure of ANP-based inhibitors – analogues of nucleoside 
monophosphates. 
 
Acyclic nucleoside phosphonates (ANPs) represent a group of compounds with 
remarkable biological activities and some of them are currently in use as antiviral agents that 
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act by inhibiting viral DNA polymerases or reverse transcriptases.
8
 The absence of a 
glycosidic bond and the phosphonate moiety replacing phosphate in these nucleotide 
analogues explains their resistance to enzymatic degradation. We proposed that replacement 
of the pyrimidine or 6-amino purine base in the structure of antiviral ANPs, by either guanine 
or hypoxanthine, results in potent and selective inhibition of Pf HGXPRT.
9
 We have since 
investigated how the inhibitory potency and selectivity versus the human enzyme is affected 
by acyclic chain length or branching of phosphonoethoxyethyl chain (Fig. 1B).
10-12
 Since 
highly conserved regions of amino acid residues are involved in the catalysis, cocrystal 
structures
9 
of ANPs interacting with the active site of human HGPRT provides an excellent 
model to design suitable new inhibitors.
 
Based on these insights, we have been able to 
synthesize new compounds that can, with a high degree of complementarity, precisely fill the 
active site of PRTases.
13
 By positioning a nitrogen atom at the branching point in the acyclic 
moiety, the route to chemical synthesis was simplified. Thus, series of aza-ANPs were 
synthesized.
14,15 
 
 
Fig. 2. Proposed mechanism of phosphoramidate prodrug cleavage.
17 
 
The presence of the phosphonate group in ANPs is responsible for their highly polar 
character and deprotonation at physiological pH. Much of the recent commercial success of 
the antiviral or cytostatic ANPs can be attributed to the development of a range of prodrug 
groups that are attached to the active compound to mask the charge of the phosphonate 
moiety. Thus, these groups facilitate transport across cell membranes and improve the 
pharmacological properties of the ANPs.
16,17
 In agreement with the literature,
 
we have 
observed that the preparation of various types of prodrugs of the parent ANP-based inhibitors 
can significantly improve the activity in cell-based antimalarial assays.
13,15
 As a prodrug of 
choice, we have selected compounds with a phosphoramidate linkage
18
 having two identical 
amino acid esters attached, to facilitate entry into the cells. Due to the presence of equivalent 
substituents attached to the phosphorus atom, there are no difficulties associated with prodrug 
  
 
 
4 
chirality. In addition, only non-toxic amino acid molecules are released after prodrug cleavage 
(Fig. 2).
17 
Several ANP-prodrugs of this type are now in clinical trials as antiviral or 
anticancer therapeutics.
19
 These compounds are able to cross the cellular membranes 
efficiently and the P-N bond is then cleaved inside the cells. Their relatively high stability in 
plasma and low cytotoxicity towards mammalian cells make them prime candidates for the 
development of chemotherapeutics against malaria parasites.  
In this paper, we report on the preparation of the phosphoramidate prodrugs of the 
series of aza-ANP-based PRTase inhibitors. In addition, synthesis of six new aza-ANPs (4g, 
4h, 4j and 5g, 5h, 5j) complementing the previously prepared
14,15
 inhibitors of Pf, Pv and 
human HG(X)PRT is described, and their inhibitory activity (PfHGXPRT and human 
HGPRT) is reported to extend our published data. According our recent findings, 
phenylalanine prodrugs are more stable in plasma and their higher lipophilicity enable better 
penetration to the cells compared to alanine used in antivirals. The pheylalanine prodrugs are 
used continuously in the whole SAR-study to allow us comparison among the various types of 
ANP-based inhibitors. All prepared phosphonate and bisphosphonate prodrugs (6a, 6c, 6j, 7a, 
7b, 7j, 8h, 8i and 9h, 9i) in this current study carry L-phenylalanine isopropyl- or ethylester 
moieties to mask the polar phosphonate groups. Their antimalarial activity was evaluated in 
erythrocyte cell cultures infected with either chloroquine-sensitive (D6) or chloroquine- 
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Scheme 1: Synthesis of ANP-based inhibitors of Pf and human HG(X)PRT and their 
phosphoramidate prodrugs. 
 
resistant (W2) strains of Pf. Their cytotoxicity in mammalian cells was determined as this is a 
crucial element in determining the potential of such compounds as drug leads. 
 
Chemistry 
 The synthesis of aza-ANP phosphoramidate prodrugs 6-9 (Scheme 1) was based on a 
recently published method.
20 
 Starting diethyl esters of phosphonates 2a-2c, 2e, 3a-3c and 3e 
were prepared as we described previously.
14
 The series was complemented with new 
bisphosphonates containing a phosphonomethyl group (2d and 3d), compounds with racemic 
dihydroxypropyl moiety mimicking the sugar scaffold (2g and 3g) and derivatives bearing an 
aryl group (2j and 3j) that could enable interaction with a tyrosine side chain that is found in a 
large mobile loop that is thought to close over the enzyme’s active site during catalysis.21 For 
the synthesis of these new derivatives, a similar procedure
14 
was applied (Scheme 1): 2-(2-
hydroxyethylamino)ethylphosphonate
14 
was N-alkylated by diisopropyl 
bromomethylphosphonate, 4-chloromethyl-2,2-dimethyl-1,3-dioxolane or ((2-
bromoethoxy)methyl)benzene, respectively, using K2CO3 as a base. Thus formed N-branched 
hydroxyderivatives 1d, 1f and 1j were attached to the N
9
-position of 6-chloropurine or 2-
amino-6-chloropurine via Mitsunobu reaction. In the case of alkylation of 2-amino-6-
chloropurine, the Mitsunobu reaction had to be followed by heating in water/tetrahydrofuran 
to decompose the triphenylphosphoranylidene intermediate rising from the presence of the 
free amino group.
22
 The resulting 6-chloropurine derivatives were transformed to 
hypoxanthine aza-ANP esters 2d, 2g and 2j by nucleophilic aromatic substitution in acidic 
conditions (75% aqueous trifluoroacetic acid). The chlorine atom of 2-amino-6-chloropurine 
derivatives was displaced with hydroxyl by the same method to form guanine aza-ANP esters 
3d, 3g and 3j. As expected, the isopropylidene protecting group was simultaneously cleaved 
from dihydroxyderivatives 2g and 3g under these acidic conditions. 
 The ester groups of the new derivatives 2d, 2g, 2j, and 3d, 3g, 3j were cleaved under 
standard conditions using Me3SiBr/acetonitrile followed by hydrolysis (Scheme 1) to form 
aza-ANP-based inhibitors 4g, 4h, 4j and 5g, 5h, 5j. The synthesis of the free phosphonic 
acids 4a-4c, 4i and 5a-5c, 5i was described in our previous paper.
14 
 
 The diethylesters of phosphonates (2a, 2c, 2j and 3a, 3b, 3j) and tetraesters of 
bisphosphonates (2d, 2e and 3d, 3e) were used for the direct preparation
20
 of the 
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phosphoramidate prodrugs 6-9 suitable for antimalarial testing in the cell-based assays. The 
selection of this particular type of phosphonate prodrug was based on our previous experience 
which led to an increase of membrane permeability and bioavailability for the antiviral 
ANPs.
16,18,23,24
 In the first step of the one-pot reaction sequence, the cleavage of the 
phosphonate esters 2 and 3 with Me3SiBr in dry pyridine under argon atmosphere forms in 
situ the corresponding trimethylsilyl esters. In the second step, the reaction of these 
intermediates with ethyl (or isopropyl for 6j and 7j) (L)-phenylalanine in the presence of 2,2′-
dithiodipyridine (Aldrithiol) and triphenylphosphine yielded the corresponding target bis-
amidates 6a, 6c, 6j and 7a, 7b, 7j and tetra-amidates 8h, 8i and 9h, 9i (Scheme 1). To prepare 
absolutely pure prodrugs for cell-based assays, the complex reaction mixtures were purified 
by column chromatography on silica gel and the crude products were further purified by 
preparative HPLC on C18 reverse phase. 
 
Inhibitory effect of the three new aza-ANPs against human HGPRT and PfHGXPRT 
and evaluation of ten new prodrugs for antimalarial activity and cytotoxicity. 
To complement previously published series, six new aza-ANPs (4g, 4h, 4j and 5g, 5h, 
5j) were synthesized with either guanine or hypoxanthine as the base. All contain a 
phosphonate group connected to the N
9
 atom of the purine base by five-atom linker (Scheme 
1). This phoshonate group has been found to occupy the 5-phosphate binding pocket in the 
active site in the 6-oxopurine PRTases.
9,13,15
 The three structural types of aza-ANPs differ in 
the substituent that is covalently attached to the nitrogen atom in the linker (Table 1). 
 
 
Table 1: Comparison of Ki values of aza-ANPs for human HGPRT and PfHGXPRT. Values 
are means  SD.  
 
Ki (M) 
B = Guanine B = Hypoxanthine            
R  human  Pf  human  Pf 
-CH2CH(OH)CH2OH 5g 0.60.2 0.60.2 4g 3.81.0 5.02.0 
-CH2P(O)(OH)2 5h 2.00.8 1.00.6 4h 10.03.0
 
6.02.0 
-CH2CH2OCH2Ph 5j 1.90.4 2.40.3 4j 13.02.0 4.30.4 
  
 
 
7 
 
All six of these ANPs inhibit both human HGPRT and PfHGXPRT. Compound 5g 
exhibited the lowest Ki value (i.e. 0.6 M) for PfHGXPRT, and thus, this scaffold has good 
potential for further development of highly potent inhibitors of this enzyme. For both 
enzymes, ANPs with guanine as the base had lower Ki values compared with those ANPs 
where hypoxanthine is the base. These ANPs exhibited similar affinity for both enzymes, 
suggesting that the interactions between the inhibitor and the active site residues could be 
identical for the two enzymes. The range of Ki values for PfHGXPRT for previously 
published inhibitors 4a-c, 4i and 5a-c, 5i was 0.1-6 M.14 
 
Table 2: In vitro antimalarial activity and cytotoxicity of the aza-ANP prodrugs.   
 
IC50 
(M) 
IC50 
(M) 
CC50 
(M) 
CC50 
(M) 
CC50 
(M) 
SI
* 
Free 
aza-ANP 
inhibitor 
R D6
a 
W2
b 
A549
c 
C32
d C32-TG
e
   
 B = Hypoxanthine  
CH2CH2COOMe 6a 3.51.0 2.91.1 709 >300 2123 >44 4a 
CH2CH2CH2CN 6c 4.21.4 5.51.6 308 10222 8912 15 4c 
CH2CH2OCH2Ph 6j 1.50.5  2.81.2 231 132 184 8 4j 
CH2P(O)(NHZ)2 
Z = CH(CH2Ph)(COOR’) 
8h 4.71.1 1.60.2 415 230 250 9 4h 
CH2CH2P(O)(NHZ)2 
Z = CH(CH2Ph)(COOR’) 
8i
 
3.10.3 2.70.3 7910 482 482 20 4i 
 B = Guanine  
CH2CH2COOMe 7a 11.81.6 5.61.8 >300 >300 >300 >34 5a 
CH2CH2CH2COOMe 7b 8.61.5 5.73.9 ≥232 23411 ≥246 >33 5b 
CH2CH2OCH2Ph 7j 1.60.2 2.91.0 204 174 231 9 5j 
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CH2P(O)(NHZ)2 
Z = CH(CH2Ph)(COOR’) 
9h 10.41.4 4.60.2 >300 6524 561 >8 5h 
CH2CH2P(O)(NHZ)2 
Z = CH(CH2Ph)(COOR’) 
9i  6.30.1 7.42.1 14483 511 535 12 5i 
a
Chloroquine-sensitive (D6) or 
b
chloroquine-resistant (W2) Plasmodium falciparum cultured 
in erythrocyte cell cultures. 
*
Estimated selectivity index = average CC50 for A549, C32 and 
C32-TG divided by the average IC50 for Pf in erythrocyte cell cultures. 
c
Human lung 
carcinoma cells 
d
Human melanoma cells 
e
Thioguanine-resistant mutant, expressing no 
functional human HGPRT due to exon-2 deletion.
25
 IC50 and CC50 values are means  SD and 
means  SEM, respectively. 
 
The antimalarial activities and cytotoxicity data for ten new prodrugs of the aza-ANPs 
are given in Table 2. The potential cytotoxicity of the prodrugs was determined in three 
human tumor cell lines, i.e. human lung carcinoma A549 cells; human C32 melanoma cells; 
and C32-TG, an HGPRT-deficient mutant form of the C32 cells. In general, the 50% 
cytotoxic concentrations (CC
50
) were very similar in the three cell lines. All ten aza-ANP 
prodrugs exhibited in vitro antimalarial activity in the micromolar range in erythrocyte cell 
cultures infected with either the chloroquine-sensitive (D6) or chloroquine-resistant (W2) 
strains of Pf. In all cases, except for the compounds with benzyl substituent 6j and 7j, the aza-
ANPs with the lowest IC50 values were those with hypoxanthine as the base. However, the 
prodrugs with the lowest cytotoxicity were those with guanine as the base. As a result of these 
preferences, compounds 6a, 7a and 7b have the best selectivity index ratios suggesting that 
they could be the optimal compounds for further development as antimalarials amongst this 
group of prodrugs. The latter two compounds showed no or marginal cytotoxicity at 
concentrations of 230-300 µM, yet produced activity against the malaria parasite in the 
concentration range 6-12 µM.  
The lowest IC50 values were for compounds 6j and 7j (approx. 1.5 M for D6 and 2.8 
M for W2), but these prodrugs also have the lowest selectivity indexes (SI: 8 and 9). For 
these prodrugs, both the IC50 values and CC50 values were the same irrespective of the purine 
base. This prodrug carries an isopropyl moiety instead of the ethyl group used in all the other 
prodrugs examined here. Thus, this data could reflect that this type of prodrug has greater cell 
permeability into the pathogen and/or that this group is more easily hydrolyzed by the 
enzymes inside the pathogen or less easily hydrolyzed by the mammalian host cell. On the 
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other hand these elusive properties could be caused also by the distinctive character of the aryl 
substituent in the side chain of 6j and 7j. 
 
Conclusions 
New aza-ANPs have been synthesized all of which inhibit human HGPRT and PfHG(X)PRT 
activity. Phosphoramidate prodrugs of these and previously published aza-ANP-based 
inhibitors are able to arrest the growth of Pf in cell culture and also possess low cytotoxicity 
in human cells.  Three prodrugs have been found from these studies that have selectivity 
indexes of >33. The findings also suggest that replacing of the ethyl group by e.g. isopropyl 
group in the prodrug design may influence the biological activity.  The results show that 
subtle differences in the chemical structure of parent ANPs and their prodrugs can have a 
significant effect on their in vitro antimalarial activity and cytotoxicity. 
 
Experimental Section 
Synthesis and Analytical Chemistry. Unless otherwise stated, solvents were evaporated at 
40 °C/2 kPa, and the compounds were dried over P
2
O
5
 at 2 kPa. NMR spectra were recorded 
on Bruker Avance 500 (
1
H at 500 MHz, 
13
C at 125.8 MHz) and Bruker Avance 400 (
1
H at 
400 MHz, 
13
C at 100.6 MHz) spectrometers with TMS as internal standard or referenced to 
the residual solvent signal. Mass spectra were measured on UPLC-MS (Waters SQD-2). 
The purity of the tested compounds was determined by HPLC (H
2
O-CH
3
CN, linear 
gradient) and combustion analysis (C, H, N) and was higher than 95%. The basic chemicals 
were obtained from commercial sources or prepared according to the published procedures. 
Preparative HPLC purifications were performed on columns packed with 7 μm C18 
reversed phase resin (Waters Delta 600 chromatograph column), 17 × 250 mm; in ca. 
200 mg batches of mixtures using gradient MeOH/H
2
O as eluent.  
 
Synthesis of hydroxyderivatives 1 - General Procedure 
To the mixture of diethyl 2-(2-hydroxyethylamino)ethylphosphonate
14
  (2 g, 8.9 mmol), 
K
2
CO
3
 (1.2 g, 8.9 mmol) and KI (0.05 g) in dry acetonitrile (30 ml) a corresponding 
halogenoderivative (10 mmol) was added. The reaction mixture was stirred at 70 
o
C for 3 
days. The solvent was then removed by evaporatation. H
2
O and CHCl
3
 were added, the 
organic layer separated, washed with brine and dried over anhydrous MgSO
4
. After filtration, 
solvent was evaporated and the residue was purified by column chromatography on silica gel 
(CHCl
3
-MeOH), the product was obtained as oil. 
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[N-(Diethyl)phosphonoethyl-N-(diisopropyl)phosphonomethyl]-2-aminoethanol (1d): 
Starting from diisopropyl bromomethylphosphonate, yield 61%. 
1
H NMR (DMSO-d6): 4.59 
m, 2 H (iPr); 4.44 t, 2 H, J = 5.4 (OH); 3.97 m, 4 H (Et); 3.45 dd, 2 H, J = 11.6 and 5.9 (H-1'); 
2.86 d, 2 H, J = 9.9 (H-5'); 2.84 m, 2 H (H-3'); 2.63 t, 2 H, J(2’,1’) = 6.0 (H-2'); 1.92 m, 2 H 
(H-4'); 1.23 m, 18 H (iPr and Et). 
13
C NMR (DMSO-d6): 69.54 and 69.47 (iPr); 60.77 and 
60.72 (Et); 59.11 (C-1'); 56.29 (C-2’); 49.78 d, J(P,C) = 160.9 (C-5'); 48.44(C-3'); 23.70 m, 4 
C (iPr); 22.03 d, J(P,C) = 134.1 (C-4'); 16.17 and 16.11 (Et). MS (ESI): m/z = 404 [M+H]
+
. 
Diethyl 2-(((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)(2-
hydroxyethyl)amino)ethylphosphonate (1f): Starting from racemic 4-chloromethyl-2,2-
dimethyl-1,3-dioxolane, yield 45%. 
1
H NMR (DMSO-d6): 4.37 t, 2 H, J = 5.2 (OH); 4.11 m, 1 
H (H-6'); 3.98 m, 4 H (Et); 3.53 m, 1 H, (H-7'a); 3.41 t, 2 H, J(1’,2’) = 5.4 (H-1'); 3.39 m, 1 
H, (H-7'b); 2.74 m, 2 H (H-3'); 2.56 t, 2 H, J(2’,1’) = 6.4 (H-2'); 2.48 m, 2 H (H-5'); 1.89 m, 2 
H (H-4'); 1.24 m, 6 H (Et). 
13
C NMR (DMSO-d6): 74.21 (C-6’); 67.45 (C-7'); 60.73 and 60.67 
(Et); 59.05 (C-1'); 56.23 and 55.81 (C-3' and C-2'); 47.78 (C-5’); 26.65 and 25.41 (Me); 22.16 
d, J(P,C) = 134.5 (C-4'); 16.17 and 16.11 (Et). MS (ESI): m/z = 340 [M+H]
+
. 
Diethyl (2-((2-(benzyloxy)ethyl)(2-hydroxyethyl)amino)ethyl)phosphonate (1j): Starting 
from ((2-bromoethoxy)methyl)benzene, yield 52%. 
1
H NMR (DMSO-d6): 7.32 m, 5 H (Ar); 
4.46 s, 2 H (CH2Ph); 4.36 t, 1 H, J = 5.4 (OH); 3.95 m, 4 H (Et); 4.48 t, 2 H, J = 6.0 (CH2O); 
3.42 m, 2 H (CH2OH); 2.74 m, 2 H (CH2N); 2.66 t, 2 H, J = 5.9 (CH2N); 2.53 t, 2 H, J = 6.2 
(CH2N); 1.89 m, 2 H (CH2P); 1.20 m, 6 H (Et). 
13
C NMR (DMSO-d6): 138.44, 128.06, 2 C, 
127.25, 127.19, 2 C (Ar); 71.93 (CH2Ph); 68.35 (CH2O); 60.69, 2 C (Et); 59.13 (CH2OH); 
55.71, 52.70 and 47.57 (CH2N); 22.42 d, J(P,C) = 134.5 (CH2P); 16.12, 2 C (Et). MS (ESI): 
m/z = 360 [M+H]
+
. 
Derivatives 1a-1c and 1e: Prepared according the literature.
14 
 
Synthesis of N
9
-substituted hypoxanthines 2 and guanines 3  - General Procedure 
To a solution of triphenylphosphine (0.9 g, 3.44 mmol) in dry THF (25 ml) cooled to –30 
o
C 
under argon atmosphere diisopropylazadicarboxylate (DIAD, 0.6 ml, 3.3 mmol) was added 
slowly. The mixture was stirred for 30 minutes and this preformed complex was added to 6-
chloropurine (0.34 g, 2.2 mmol) or 2-amino-6-chloropurine (0.37 g, 2.2 mmol), dry THF (25 
ml) and corresponding hydroxyderivative 1 (1.9 mmol) at –30 
o
C under argon. The resulting 
mixture was slowly warmed to room temperature and stirred for 3 days. (In the case of 2-
amino-6-chloropurine derivatives, water (10 ml) was then added and the mixture was heated 
at 80 
o
C for additional 30 h.) Solvent was evaporated and the crude mixture was purified by 
  
 
 
11 
chromatography on silica gel (MeOH-CHCl
3
) and intermediates were characterized. Thus 
obtained 6-chloropurine or 2-amino-6-chloropurine intermediate was dissolved in 
trifluoroacetic acid (aqueous, 75%, 20 ml) and stirred overnight. The solvent was evaporated 
and the residue codistilled with water (3x) and ethanol. After chromatography on silica gel 
(MeOH-CHCl
3
) the pure hypoxanthine or guanine derivative was obtained as colorless foam.  
9-[{N-(Diethyl)phosphonoethyl-N-(diisopropyl)phosphonomethyl}-2-
aminoethyl]hypoxanthine (2d): Starting from 1d and 6-chloropurine, yield 53% in two 
steps. 
1
H NMR (DMSO-d6): 12.28 s, 1 H (NH); 8.13 s, 1 H and 8.03 s, 1 H (H-2 and H-8); 
4.50 m, 2 H (iPr); 4.19 t, 2 H, J(1’,2’) = 5.8 (H-1'); 3.93 m, 4 H (Et); 2.96 t, 2 H, J(2’,1’) = 5.8 
(H-2'); 2.90 d, 2 H, J = 10.1 (H-5’); 2.79 m, 2 H (H-3'); 2.74 m, 2 H (H-4'); 1.19 m, 18 H (iPr 
and Et). 
13
C NMR (DMSO-d6): 156.55 (C-6); 148.23 (C-4); 145.16 (C-2); 140.67 (C-8); 
123.66 (C-5); 69.62 and 69.55 (iPr); 60.85 and 60.79 (Et); 53.36 (C-2'); 49.37 d, J(P,C) = 
159.9 (C-5'); 48.02 (C-3'); 41.24 (C-1'); 23.68 m, 4 C (iPr); 21.89 d, J(P,C) = 134.1 (C-4'); 
16.15 and 16.09 (Et). MS (ESI): m/z = 522 [M+H]
+
. 
Diethyl 2-((2,3-dihydroxypropyl)(2-(hypoxanthin-9-yl)ethyl)amino)ethylphosphonate 
(2g): Starting from 1f and 6-chloropurine, isopropylidene protecting group was cleaved under 
acidic conditions as expected, yield 50% in two steps. 
1
H NMR (DMSO-d6): 12.32 s, 1 H 
(NH); 8.12 s, 1 H and  8.03 s, 1 H (H-2 and H-8); 4.17 m, 2 H, (H-1'); 3.94 m, 4 H (Et); 3.41 
m, 2 H (H-6'); 3.20 m, 2 H, (H-7'); 2.85 m, 2 H (H-2'); 2.69 m, 2 H (H-3'); 2.55 m, 1 H and 
2.39 m, 1 H (H-5'); 1.76 m, 2 H (H-4'); 1.20 m, 6 H (Et). 
13
C NMR (DMSO-d6): 156.58 (C-6); 
148.24 (C-4); 145.24 (C-2); 140.71 (C-8); 123.71 (C-5); 69.38 (C-6’); 63.78 (C-7'); 60.88 and 
60.82 (Et); 56.29 and 53.22 (C-3' and C-2'); 47.54 (C-5’); 39.14 (C-1'); 20.90 d, J(P,C) = 
124.6 (C-4'); 16.17 and 16.11(Et). HRMS calcd. for C16H29N5O6P: 418.18500; found: 
418.18498. MS (ESI): m/z = 418 [M+H]
+
. 
Diethyl (2-((2-(benzyloxy)ethyl)(2-(hypoxanthin-9-yl)ethyl)amino)ethyl)phosphonate 
(2j): Starting from 1j, yield 52%. 
1
H NMR (DMSO-d6): 12.27 s, 1 H (NH); 8.08 s, 1 H and  
8.01 s, 1 H (H-2 and H-8); 7.29 m, 5 H (Ar); 4.37 s, 2 H (CH2Ph); 4.16 m, 2 H, (H-1'); 3.92 
m, 4 H (Et); 3.38 m, 2 H (H-6'); 2.85 m, 2 H, (H-2'); 2.67 m, 4 H (H-3' and H-5); 1.77 m, 2 H 
(H-4'); 1.18 m, 6 H (Et). 
13
C NMR (DMSO-d6): 156.53 (C-6); 148.23 (C-4); 145.19 (C-2); 
140.67 (C-8); 135.91, 128.08, 2 C, 127.38, 127.30, 2 C (Ar); 123.69 (C-5); 71.99 (C-Ph); 
69.17 (C-6’); 60.82, 2 C (Et); 52.11, 52.09 and 47.43 (C-5’, C-3' and C-2'); 40.81 (C-1'); 
20.89 d, J(P,C) = 128.4 (C-4'); 16.13, 2 C (Et). MS (ESI): m/z = 478 [M+H]
+
. 
Hypoxanthine derivatives 2a-2c and 2e: Prepared according the literature.
14 
9-[{N-(Diethyl)phosphonoethyl-N-(diisopropyl)phosphonomethyl}-2-aminoethyl]guanine 
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(3d): Starting from 1d and 2-amino-6-chloropurine, yield 75% in two steps. 
1
H NMR 
(DMSO-d6): 10.61 s, 1 H (NH); 7.73 s, 1 H (H-8); 6.48 s, 2 H (NH2); 4.53 m, 2 H (iPr); 3.99 
t, 2 H, J(1’,2’) = 6.0 (H-1'); 3.93 m, 4 H (Et); 2.90 d, 2 H, J = 10.3 (H-5'); 2.88 m, 2 H (H-2'); 
2.79 m, 2 H (H-3'); 1.74 m, 2 H (H-4'); 1.20 m, 18 H (iPr and Et). 
13
C NMR (DMSO-d6): 
156.72 (C-6); 153.39 (C-2); 150.99 (C-4); 137.85 (C-8); 116.29 (C-5); 69.64 and 69.57 (iPr); 
60.88 and 60.82 (Et); 53.39 (C-2’); 49.41 d, J(P,C) = 159.9 (C-5'); 48.15 (C-3'); 40.79 (C-1'); 
23.69 (iPr); 22.10 d, J(P,C) = 134.3 (C-4'); 16.16 and 16.10 (Et). MS (ESI): m/z = 537 
[M+H]
+
. 
Diethyl 2-((2,3-dihydroxypropyl)(2-(guanin-9-yl)ethyl)amino)ethylphosphonate (3g): 
Starting from 1f and 2-amino-6-chloropurine, isopropylidene protecting group was cleaved 
under acidic conditions as expected, yield 56% in two steps. 
1
H NMR (DMSO-d6): 11.08 s, 1 
H (NH); 8.02 s, 1 H (H-8); 6.75 s, 2 H (NH2); 4.40 t, 2 H, J(1',2') = 5.1 (H-1'); 4.03 m, 4 H 
(Et); 3.89 m, 1 H (H-6'); 3.64 m, 2 H, (H-7'); 3.43 m, 3 H (H-2' and H-5'a); 3.34 m, 2 H (H-
3'); 3.21 m, 1 H (H-5'b); 2.32 m, 2 H (H-4'); 1.25 m, 6 H (Et). 
13
C NMR (DMSO-d6): 155.96 
(C-6); 153.99 (C-2); 150.55 (C-4); 137.33 (C-8); 114.72 (C-5); 66.02 (C-6’); 63.46 (C-7'); 
61.69 and 61.63 (Et); 55.17 and 51.53 (C-3' and C-2'); 48.22 (C-5’); 38.29 (C-1'); 21.16 d, 
J(P,C) = 134.0 (C-4'); 16.12 and 16.06(Et). MS (ESI): m/z = 433 [M+H]
+
. 
Diethyl (2-((2-(benzyloxy)ethyl)(2-(guanin-9-yl)ethyl)amino)ethyl)phosphonate (3j): 
Starting from 1j, yield 71%. 
1
H NMR (DMSO-d6): 10.56 s, 1 H (NH); 7.68 s, 1 H (H-8); 7.29 
m, 5 H (Ar); 6.43 s, 2 H (NH2); 4.39 s, 2 H (CH2Ph); 3.98 m, 2 H, (H-1'); 3.92 m, 4 H (Et); 
3.42 m, 2 H (H-6'); 2.83 m, 2 H, (H-2'); 2.73 m, 4 H (H-3' and H-5’); 1.81 m, 2 H (H-4'); 1.18 
m, 6 H (Et). 
13
C NMR (DMSO-d6): 156.67 (C-6); 153.34 (C-2); 150.95 (C-4); 138.22 (Ar); 
137.89 (C-8); 128.09, 2 C, 127.33, 2 C, 127.26 (Ar); 116.24 (C-5); 72.02 (C-Ph); 72.00 (C-
6’); 60.83, 2 C (Et); 52.51, 52.17 and 47.43 (C-5’, C-3' and C-2'); 39.81 (C-1'); 22.36 d, 
J(P,C) = 138.7 (C-4'); 16.13, 2 C (Et). MS (ESI): m/z = 493 [M+H]
+
. 
Guanine derivatives 3a-3c and 3e: Prepared according the literature.
14 
 
Synthesis of the free phosphonic acids – General Procedure 
A mixture of the corresponding diester 2 or 3 (1 mmol), acetonitrile (20 ml) and BrSiMe
3
 (1 
ml) was stirred for 2 days at room temperature. After evaporation and codistillation with 
acetonitrile, the residue was treated with aqueous methanol (2 : 1, 30 ml) for 1 h and 
evaporated. The residue was purified by preparative HPLC (water-methanol).  
2-((2,3-Dihydroxypropyl)(2-(hypoxanthin-9-yl)ethyl)amino)ethylphosphonic acid (4g): 
Starting from 2g, yield 67%. 
1
H NMR (DMSO-d6): 12.32 s, 1 H (NH); 8.15 s, 1 H and  8.04 s, 
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1 H (H-2 and H-8); 4.29 t, 2 H, J(1',2') = 6.2 (H-1'); 3.53 m, 1 H (H-6'); 3.23 m, 2 H, (H-7'); 
3.03 t, 2 H, J(2',1') = 6.2 (H-2'); 2.89 m, 2 H (H-3'); 2.71 m, 1 H and 2.56 m, 1 H (H-5'); 1.64 
m, 2 H (H-4'). 
13
C NMR (DMSO-d6): 156.55 (C-6); 148.22 (C-4); 145.33 (C-2); 140.67 (C-8); 
123.70 (C-5); 68.45 (C-6’); 63.80 (C-7'); 56.28 and 52.91 (C-3' and C-2'); 48.95 (C-5’); 40.73 
(C-1'); 24.54 d, J(P,C) = 131.0 (C-4'). HRMS calcd. for C12H19N5O6P: 360.10784; found: 
360.10761. MS (ESI): m/z = 360 [M-H]
-
. 
9-[(N-Phosphonoethyl-N-phosphonomethyl)-2-aminoethyl]hypoxanthine (4h): Starting 
from 2d, yield 55%. 
1
H NMR (DMSO-d
6
): 12.47 s, 1 H (NH); 8.30 s, 1 H and 8.10 s, 1 H (H-2 
and H-8); 4.51 t, 2 H, J(1’,2’) = 6.0 (H-1’); 3.53 t, 2 H, J(2’,1’) = 6.0 (H-2'); 3.35 d, 2 H, J = 
12.8, (H-5'); 3.50 m, 2 H (H-3'); 1.96 m, 2 H (H-4'). 
13
C NMR (DMSO-d
6
): 156.15 (C-6); 
148.15 (C-4); 145.98 (C-2); 140.33 (C-8); 122.99 (C-5); 53.04 and 50.23 (C-2' and C-3'); 
48.94 d, J(P,C) = 146.4 (C-5’); 23.41 d, J(P,C) = 133.6 (C-4’). HRMS calcd. for 
C
10
H
16
N
5
O
7
P
2
: 380.05304; found: 380.05285. MS (ESI): m/z = 380 [M-H]
-
. 
(2-((2-(Benzyloxy)ethyl)(2-(hypoxanthin-9-yl)ethyl)amino)ethyl)phosphonate (4j): 
Starting from 2j, yield 65%. 
1
H NMR (DMSO-d6): 12.31 s, 1 H (NH); 8.08 s, 1 H and  8.01 s, 
1 H (H-2 and H-8); 7.28 m, 5 H (Ar); 4.39 s, 2 H (CH2Ph); 4.25 t, 2 H, J(1’,2’) = 6.1 (H-1'); 
3.44 t, 2 H, J(6’,5’) = 5.4 (H-6'); 3.01 t, 2 H, J(2’,1’) = 6.1 (H-2'); 2.88 m, 2 H (H-3'); 2.83 t, 2 
H, J(5’,6’) = 5.4 (H-5'); 1.65 m, 2 H (H-4'). 13C NMR (DMSO-d6): 156.54 (C-6); 148.24 (C-
4); 145.27 (C-2); 140.60 (C-8); 138.11, 128.10, 2 C, 127.33, 2 C and 127.27 (Ar); 123.69 (C-
5); 71.99 (C-Ph); 67.33 (C-6’); 52.30, 52.13 and 48.57 (C-5’, C-3' and C-2'); 40.87 (C-1'); 
24.58 d, J(P,C) = 131.9 (C-4'). MS (ESI): m/z = 420 [M-H]
-
. 
 Phosphonic acids 4a-4c and 4i: Prepared previously.
14 
2-((2,3-Dihydroxypropyl)(2-(guanin-9-yl)ethyl)amino)ethylphosphonic acid (5g): Starting 
from 3g, yield 46%. 
1
H NMR (DMSO-d6): 10.76 s, 1 H (NH); 7.75 s, 1 H (H-8); 6.62 s, 2 H 
(NH2); 4.24 m, 2 H, (H-1'); 3.76 m, 1 H (H-6'); 3.30 m, 6 H, (H-7', H-2' and H-3'); 3.05 m, 1 
H (H-5'a); 2.35 m, 1 H (H-5'b); 1.86 m, 2 H (H-4'). 
13
C NMR (DMSO-d6): 156.66 (C-6); 
153.57 (C-2); 150.89 (C-4); 137.55 (C-8); 116.25 (C-5); 67.11 (C-6’); 63.66 (C-7'); 55.85 and 
52.40 (C-3' and C-2'); 49.07 (C-5’); 23.60 d, J(P,C) = 131.6 (C-4'). HRMS calcd. for 
C12H20N6O6P: 375.11874; found: 375.11830. MS (ESI): m/z = 375 [M-H]
-
. 
9-((N-Phosphonoethyl-N-phosphonomethyl)-2-aminoethyl)guanine (5h): Starting from 
3d, yield 71%. 
1
H NMR (DMSO-d
6
): 11.53 (NH); 9.04 s, 1 H (H-8); 7.30 (NH
2
); 4.51 t, 2 H, 
J(1’,2’) = 6.0 (H-1’); 3.63 t, 2 H, J(2’,1’) = 6.0 (H-2'); 3.50 m, 4 H (H-3' and H-5'); 2.03 m, 2 
H (H-4'). 
13
C NMR (DMSO-d
6
): 155.13 (C-6); 153.72 (C-2); 149.66 (C-4); 137.63 (C-8); 
115.98 (C-5); 53.91 and 50.01 (C-2' and C-3'); 48.64 d, J(P,C) = 146.2 (C-5’); 40.34 (C-1'); 
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23.06 d, J(P,C) = 132.45 (C-4’). HRMS calcd. for C
10
H
17
N
6
O
7
P
2
: 395.06394; found: 
395.06342. MS (ESI): m/z = 395 [M-H]
-
. 
(2-((2-(Benzyloxy)ethyl)(2-(guanin-9-yl)ethyl)amino)ethyl)phosphonate (5j): Starting 
from 3j, yield 51%. 
1
H NMR (DMSO-d
6
): 10.62 s, 1 H (NH); 7.68 s, 1 H (H-8); 7.30 m, 5 H 
(Ar); 6.54 s, 2 H (NH2); 4.41 s, 2 H (CH2Ph); 4.08 t, 2 H, J(1’,2’) = 5.9 (H-1'); 3.50 t, 2 H, 
J(6’,5’) = 5.3  (H-6'); 3.02 t, 2 H, J(2’,1’) = 5.9 (H-2'); 2.97 m, 4 H (H-3'); 2.90 t, 2 H, J(5’,6’) 
= 5.3 (H-5'); 1.72 m, 2 H (H-4'). 
13
C NMR (DMSO-d6): 156.68 (C-6); 153.46 (C-2); 150.96 
(C-4); 138.04 (Ar); 137.67 (C-8); 128.13, 2 C, 127.59, 127.31, 2 C (Ar); 116.24 (C-5); 72.05 
(C-Ph); 66.94 (C-6’); 52.37, 52.18 and 48.68 (C-5’, C-3' and C-2'); 39.80 (C-1'); 24.47 d, 
J(P,C) = 130.4 (C-4'). MS (ESI): m/z = 435 [M-H]
-
. 
Phosphonic acids 5a-5c and 5i: Prepared previously.
14 
 
Synthesis of bisphosphoramidate prodrugs of phosphonic acids  6 and 7  - General 
procedure 
A mixture of corresponding diester 2 or 3 (0.5 mmol), dry pyridine (8 ml) and BrSiMe
3
 (0.4 
ml) was stirred overnight at room temperature under argon. After evaporation and 
codistillation with pyridine under argon atmosphere, the residue was dissolved in dry pyridine 
(5 ml) and ethyl (L)-phenylalamine hydrochloride (0.5 g, 2.1 mmol) and triethylamine (1 ml) 
were added. The mixture was heated to 70 
o
C under argon atmosphere and then solution of 
Aldrithiol (0.66 g, 3 mmol) and triphenylphosphine (0.8 g, 3 mmol) in dry pyridine (5 ml) 
was added. The reaction mixture was heated at 60 
o
C for 2 days, the solvent was evaporated 
and the residue was purified by column chromatography on silica gel and the crude product 
further purified by preparative HPLC. The phosphoramidate prodrug was obtained as foam. 
(2S,2'S)-Diethyl 2,2'-{[2-((3-methoxy-3-oxopropyl)(2-(hypoxanthin-9-
yl)ethyl)amino)ethyl]phosphoryl}bis(azanediyl)bis(3-phenylpropanoate) (6a): Starting 
from 2a, yield 85%. 
1
H NMR (DMSO-d6): 12.26 s, 1 H (NH); 8.02 s, 1 H and 7.99 s, 1 H (H-
8 and H-2); 7.20 m, 10 H (Ar); 4.51 t, 1 H, J = 11.2 (NH); 4.19 t, 2 H, J = 10.6 (NH); 4.09 t, 2 
H, J(1’,2’) = 6.2 (H-2’); 4.02 q, 4 H, J = 7.1 (Et); 4.01 m, 1 H and 3.87 m, 1 H (CH); 3.53 s , 
3 H (Me); 2.87 m, 3 H and 2.75 m, 1 H (CH2Ph); 2.56 t, 2 H, J(5’,6’) = 7.0 (H-5’); 2.62 t, 2 
H, J(2’,1’) = 6.2 (H-2’); 2.43 m, m, 2 H (H-3'); 2.24 t, 2 H, J(6’,5’) = 7.1 (H-6’); 1.33 m, 2 H 
(H-4'); 1.11 t, 3 H and 1.06 t, 3 H, J = 7.1 (Et). 
13
C NMR (DMSO-d6): 173.09, 172.92 and 
172.16 (CO); 156.56 (C-6); 148.17 (C-4); 145.17 (C-2); 140.48 (C-8); 137.21, 137.11,  
129.30, 2 C, 129.24, 2 C, 127.98, 2 C, 127.94, 2 C, 126.35 and 126.26 (Ar); 123.69 (C-5); 
60.21 and 60.11 (Et); 53.94 and 53.82 (NHCH); 51.90 (C-2’); 51.08 (Me); 47.89 (C-5');  
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46.76 (C-3'); 41.16 (C-1'); 31.51 (C-7'); 25.92 (C-6'); 21.52, J(P,C) = 136.3 (C-4’); 13.83 and 
13.78 (Et). HRMS calcd. for C35H47N7O8P: 724.32182; found: 724.32161. MS (ESI): m/z = 
724 [M+H]
+
. 
(2S,2'S)-Diethyl 2,2'-{[2-((3-cyanopropyl)(2-(hypoxanthin-9-
yl)ethyl)amino)ethyl]phosphoryl}bis(azanediyl)bis(3-phenylpropanoate) (6c): Starting 
from 2c, yield 58%. 
1
H NMR (DMSO-d6): 12.30 s, 1 H (NH); 8.04 s, 1 H and 8.02 s, 1 H (H-
8 and H-2); 7.21 m, 10 H (Ar); 4.52 t, 1 H, J = 11.6 (NH); 4.20 t, 2 H, J = 11.6 (NH); 4.11 t, 2 
H, J(1’,2’) = 6.2 (H-2’); 4.03 q, 4 H, J = 7.1 (Et); 3.98 m, 1 H and 3.89 m, 1 H (CH); 2.86 m, 
3 H and 2.75 m, 1 H (CH2Ph); 2.63 t, 2 H, J(2’,1’) = 6.2 (H-2’); 2.48 m, 1 H and 2. 39 m, 1 H 
(H-3'); 2.30 t, 2 H, J(5’,6’) = 6.7 (H-5’); 2.18 t, 2 H, J(7’,6’) = 7.2 (H-7’); 1.45 m, 2 H (H-6'); 
1.36 m, 2 H (H-4'); 1.12 t, 3 H and 1.07 t, 3 H, J = 7.1 (Et). 
13
C NMR (DMSO-d6): 173.04 and 
172.85 (CO); 156.49 (C-6); 147.38 (C-4); 145.20 (C-2); 140.44 (C-8); 137.08, 2 C, 129.27, 2 
C, 129.22, 2 C, 127.96, 2 C, 127.93, 2 C, 126.33 and 126.24 (Ar); 120.29 (C-5); 118.24 (CN); 
60.20 and 60.11 (Et); 53.87 and 53.81 (NHCH); 51.88 (C-2’); 50.98 (C-5');  46.63 (C-3'); 
42.07 (C-1'); 41.18 (CH2Ph); 22.56 (C-7'); 13.80 and 13.77 (Et); 13.50 (C-6'). HRMS calcd. 
for C35H46N8O6P: 705.32724; found: 705.32730. MS (ESI): m/z = 705 [M+H]
+
. 
(2S,2'S)-Diisopropyl 2,2'-{[2-((2-(benzyloxy)ethyl)(2-(hypoxanthin-9-
yl)ethyl)amino)ethyl]phosphoryl}bis(azanediyl)bis(3-phenylpropanoate) (6j): Starting 
from 2j, yield 76%. 
1
H NMR (DMSO-d6): 12.27 s, 1 H (NH); 8.02 s, 1 H and 7.99 s, 1 H (H-8 
and H-2); 7.20 m, 15 H (Ar); 4.80 m, 2 H (iPr); 4.47 t, 1 H, J = 11.5 (NH); 4.36 s, 2 H 
(CH2Ph); 4.17 t, 2 H, J = 11.5 (NH); 4.11 t, 2 H, J(1’,2’) = 6.2 (H-1’); 3.97 m, 1 H and 3.84 
m, 1 H (CH); 3.30 t, 2 H, J(6’,5’) = 5.9 (H-6’); 2.85 m, 3 H and 2.74 m, 1 H (CH2Ph); 2.72 t, 
2 H, J(2’,1’) = 6.2 (H-2’); 2.54 t, 2 H, J(5’,6’) = 5.9 (H-5’); 2.44 m, 2 H (H-3'); 1.38 m, 2 H 
(H-4'); 1.10 m, 12 H (iPr). 
13
C NMR (DMSO-d6): 172.49, 2 C (CO); 156.54 (C-6); 148.17 (C-
4); 145.14 (C-2); 140.51 (C-8); 138.29, 137.10, 2 C, 129.27, 2 C, 129.32, 2 C, 129.28, 2 C, 
128.07, 2 C, 127.96, 2 C, 127.91, 2 C, 127.23, 2 C, 126.34 and 126.25 (Ar); 123.66 (C-5); 
71.95 (C-Ph); 68.13 (C-6’); 67.71 and 67.55 (iPr); 54.02 and 53.84 (NHCH); 52.73 (C-2’); 
52.08 (C-5');  47.77 (C-3'); 41.27 (C-1'); 40.00, 2 C (CH2Ph); 25.91, J(P,C) = 109.7 (C-4’); 
21.29 m, 4 C (iPr). MS (ESI): m/z = 800 [M+H]
+
. 
 (2S,2'S)-Diethyl 2,2'-{[2-((2-(guanin-9-yl)ethyl)(3-methoxy-3-
oxopropyl)amino)ethyl]phosphoryl}bis(azanediyl)bis(3-phenylpropanoate) (7a): Starting 
from 3a, yield 40%. 
1
H NMR (DMSO-d6): 10.55 s, 1 H (NH); 7.59 s, 1 H (H-8); 7.20 m, 10 H 
(Ar); 6.46 s, 2 H (NH2); 4.54 t, 1 H, J = 11.6 (NH); 4.18 t, 1 H, J = 11.8 (NH); 4.02 q, 4 H, J 
= 7.3 (Et); 3.97 m, 1 H (NHCH); 3.87 m, 3 H (NHCH and H-1'); 3.55 s, 3 H (Me); 2.87 m, 3 
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H and 2.71 m, 1 H (CH2Ph); 2.56 m, 2 H (H-2’ and H-5'); 2.45 m, 2 H (H-3'); 2.28 t, 2 H, 
J(6’,5’) = 6.9 (H-6'); 1.37m, 2 H (H-4'); 1.11 t, 3 H and 1.06 t, 3 H (Et). 13C NMR (DMSO-
d6): 173.08, 172. 90 and 172.24 (CO); 156.71 (C-6); 153.32 (C-2); 150.95 (C-4); 137.60 (C-
8); 137.21, 137.11, 129.29, 2 C, 129.24, 2 C, 127.99, 2 C, 127.94, 2 C, 126.36 and 126.27 
(Ar); 116.29 (C-5); 60.21 and 60.11 (Et); 53.98 and 53.83 (NHCH); 51.90 (C-2’); 51.12 (Me); 
47.91 (C-5');  46.64 (C-3'); 40.53 (C-1'); 31.54 (C-6'); 13.83 and 13.77 (Et). HRMS calcd. for 
C35H48N8O8P: 739.33272; found: 739.33281. MS (ESI): m/z = 739 [M+H]
+
. 
(2S,2'S)-Diethyl 2,2'-{[2-((2-(guanin-9-yl)ethyl)(4-methoxy-4-
oxobutyl)amino)ethyl]phosphoryl}bis(azanediyl)bis(3-phenylpropanoate) (7b): Starting 
from 3b, yield 41%. 
1
H NMR (DMSO-d6): 10.53 s, 1 H (NH); 7.61 s, 1 H (H-8); 7.21 m, 10 H 
(Ar); 6.42 s, 2 H (NH2); 4.53 m, 1 H (NH); 4.20 m, 1 H (NH); 4.02 q, 4 H, J = 7.1 (Et); 3.97 
m and 3.87 m, 4 H (H-1'and NHCH); 3.56 s, 3 H (Me); 3.88 m, 2 H (NHCH); 2.86 m, 3 H and 
2.75 m, 1 H (CH2Ph); 2.54 m, 2 H (H-2’); 2.40 m, 2 H (H-5’); 2.23 m, 2 H (H-3'); 2.11 m, 2 
H (H-7'); 1.44 m, 2 H (H-6'); 1.35 m, 2 H (H-4'); 1.12 t, 3 H and 1.06 t, 3 H, J = 7.1 (Et). 
13
C 
NMR (DMSO-d6): 173.38 and 173.36 (CO); 156.98 (C-6); 153.65 (C-2); 151.23 (C-4); 
137.88 (C-8); 137.48, 137.39, 129.59, 2 C, 129.55, 2 C, 128.30, 2 C, 128.25, 2 C, 126.68 and 
126.59 (Ar); 116.65 (C-5); 60.52 and 60.42 (Et); 54.27 and 54.14 (NHCH); 51.81 (C-2’); 
51.38 (Me); 47.01 (C-5');  44.10 (C-3'); 30.91 (C-7'); 24.36 d, J(P,C) = 124.0 (C-4’); 22.26 
(C-6'). 14.13 and 14.07 (Et). HRMS calcd. for C36H50N8O8P: 753.34837; found: 753.34843. 
MS (ESI): m/z = 753 [M+H]
+
. 
(2S,2'S)-Diethyl 2,2'-{[2-((2-(benzyloxy)ethyl)(2-(guanin-9-
yl)ethyl)amino)ethyl]phosphoryl}bis(azanediyl)bis(3-phenylpropanoate) (7j): Starting 
from 3j, yield 61%. 
1
H NMR (DMSO-d6): 10.54 s, 1 H (NH); 7.62 s, 1 H (H-8); 7.20 m, 15 H 
(Ar); 6.43 s, 2 H (NH2); 4.78 m, 2 H (iPr); 4.50 t, 1 H, J = 11.5 (NH); 4.37 s, 2 H (CH2Ph); 
4.19 t, 2 H, J = 11.5 (NH); 3.90 t, 2 H, J(1’,2’) = 6.2 (H-1’); 3.87 m, 2 H (CH); 3.33 t, 2 H, 
J(6’,5’) = 6.0 (H-6’); 2.85 m, 3 H and 2.72 m, 1 H (CH2Ph); 2.64 t, 2 H, J(2’,1’) = 6.2 (H-2’); 
2.53 t, 2 H, J(5’,6’) = 6.0 (H-5’); 2.45 m, 2 H (H-3'); 1.42 m, 2 H (H-4'); 1.08 m, 12 H (iPr). 
13
C NMR (DMSO-d6): 172.50, 2 C (CO); 156.74 (C-6); 153.33 (C-2); 150.97 (C-4); 138.33 
(Ar); 137.64 (C-8); 137.08, 2 C, 129.32, 2 C, 129.28, 2 C, 128.08, 2 C, 127.96, 2 C, 127.91, 2 
C, 127.28, 2 C, 127.22, 2 C; 126.35 and 126.26 (Ar); 116.29 (C-5); 71.99 (C-Ph); 68.18 (C-
6’); 67.72 and 67.56 (iPr); 54.06 and 53.84 (NHCH); 52.71 (C-2’); 52.14 (C-5');  47.74 (C-3'); 
40.66 (C-1'); 40.00, 2 C (CH2Ph); 25.90, J(P,C) = 111.3 (C-4’); 21.28 m, 4 C (iPr). MS (ESI): 
m/z = 815 [M+H]
+
. 
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Synthesis of tetraphosphoramidate prodrugs of bisphosphonic acids  8 and 9 - General 
procedure 
A mixture of corresponding tetraester 2d, 2e or 3d, 3e (0.5 mmol), dry pyridine (8 ml) and 
BrSiMe
3
 (1 ml) was stirred overnight at room temperature under argon. After evaporation and 
codistillation with pyridine under argon atmosphere, the residue was dissolved in dry pyridine 
(8 ml) and ethyl (L)-phenylalamine hydrochloride (1.4 g, 10 mmol) and triethylamine (2.5 ml) 
were added. The mixture was heated to 70 
o
C under argon atmosphere and then solution of 
Aldrithiol (1.85 g, 8 mmol) and triphenylphosphine (2.1 g, 8 mmol) in dry pyridine (8 ml) 
was added. The reaction mixture was heated at 70 
o
C for 3 days, the solvent was evaporated 
and the residue was purified by column chromatography on silica gel and the crude product 
further purified by preparative HPLC. The phosphoramidate prodrug was obtained as foam. 
Tetra-(ethyl L-phenylalanine) prodrug of 9-[(N-Phosphonoethyl-N-phosphonomethyl)-2-
aminoethyl]hypoxanthine (8h): Starting from 2d, yield 20%. 
1
H NMR (DMSO-d6): 12.27 s, 
1 H (NH); 8.08 s, 1 H and 7.99 s, 1 H (H-8 and H-2); 7.19 m, 20 H (Ar); 4.51 m, 1 H, 4.35 m, 
1 H and 4.07 m, 2 H (NH); 3.99 m, 14 H (H-1', NHCH and Et); 2.55-2.90 m, 12 H (CH2Ph, 
H-2' and H-5'); 2.26 m, 2 H (H-3'); 1.30 m, 2 H (H-4'); 1.06 m, 12 H and (Et). 
13
C NMR 
(DMSO-d6): 172.81 m (CO); 156.52 (C-6); 148.17 (C-4); 145.16 (C-2); 140.32 (C-8); 137.09, 
2 C, 137.03, 2 C,  129.27, 4 C, 129.20, 4 C, 127.96, 4 C, 127.92, 4 C, 126.32, 2 C and 126.24, 
2 C (Ar); 123.69 (C-5); 60.15 m (Et); 53.78 m (NHCH); 51.37 (C-2’); 49.83, J(P,C) = 162.9 
(C-5’); 45.99 (C-3'); 41.06 (C-1'); 13.77 and 13.73 (Et). HRMS calcd. for C54H70N9O11P2: 
1082.46645; found: 1082.46721. MS (ESI): m/z = 1083 [M+H]
+
. 
Tetra-(ethyl L-phenylalanine) prodrug of 9-[(N,N-(bis-2-phosphonoethyl))-2-
aminoethyl]hypoxanthine (8i): Starting from 2e, yield 25%. 
1
H NMR (DMSO-d6): 12.28 s, 
1 H (NH); 8.00 m, 2 H (H-2 and H-8); 7.19 m, 20 H (Ar); 4.-11-4.52 m, 4 H (NH); 3.75-4.07 
m, 14 H (H-1', Et, NHCH); 2.88 m, 6 H and 2.77 m, 2 H (CH2Ph); 2.52 m, 2 H (H-2'); 2.39 m, 
4 H (H-3', H-5’); 1.35 m, 4 H (H-4', H-6'); 1.08 m, 12 H (Et). 13C NMR (DMSO-d6): 173.42, 
173.33, 173.19 and 173.15 C (CO); 156.84 (C-6); 148.44 (C-4); 145.51(C-2); 140.65 (C-8); 
137.43, 2 C, 137.33, 2 C 129.56, 4 C, 129.52, 4 C, 128.28, 4 C, 128.26, 4 C, 126.65, 2 C and 
126.62, 2 C (Ar); 123.99 (C-5); 60.51 and 60.42, 4 C (Et); 54.22 m, 4 C (NHCH); 51.84 (C-
2’); 46.63 and 46.58 (C-3' and C-5'); 41.19 (C-1'); 24.91 d, J(P,C) = 144.03 (C-4’ and C-6'); 
14.11 and 14.07, 4 C (Et). HRMS calcd. for C55H72N9O11P2: 1096.48265; found: 1096.48260. 
MS (ESI): m/z = 1096 [M+H]
+
. 
Tetra-(ethyl L-phenylalanine) prodrug of 9-[(N-Phosphonoethyl-N-phosphonomethyl)-2-
aminoethyl]guanine (9h): Starting from 3d, yield 20%. 
1
H NMR (DMSO-d6): 10.55 s, 1 H 
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(NH); 7.67 s, 1 H (H-8); 7.15 m, 20 H (Ar); 6.44 s, 2 H (NH2); 4.55 m, 1 H, 4.33 m, 1 H, 4.14 
m, 1 H and 4.08 m, 1 H (NH); 3.78-4.03 m, 14 H (H-1', NHCH, Et); 2.81 m, 8 H (CH2Ph); 
2.56 m, 4 H (H-2’, H-3'); 2.25 d, 2 H, J = 10.8 (H-5'); 1.36 m, 2 H (H-4'); 1.06 m, 12 H and 
(Et). 
13
C NMR (DMSO-d6): 173.20 m (CO); 157.06 (C-6); 153.69 (C-2); 151.28 (C-4); 
137.81 (C-8); 137.22, 2 C, 137.50, 2 C, 129.54, 4 C, 129.66, 4 C, 128.27, 4 C, 128.35, 4 C, 
126.53, 2 C and 126.74, 2 C (Ar); 116.61 (C-5); 60.55 m (Et); 54.23 m (NHCH, C-2'); 52.28 
d, J = 132.3 (C-5');  49.14 (C-3'); 40.73 (C-1'); 40.29 m (CH2Ph); 24.43 d, J = 110.6 (C-4’); 
14.06 and 14.12 (Et). HRMS calcd. for C54H71N10O11P2: 1097.47735; found: 1097.47834. MS 
(ESI): m/z = 1097 [M+H]
+
. 
Tetra-(ethyl L-phenylalanine) prodrug of 9-[(N,N-(bis-2-phosphonoethyl))-2-
aminoethyl]guanine (9i): Starting from 3e, yield 70%. 
1
H NMR (DMSO-d6): 10.56 s, 1 H 
(NH); 7.19 s, 1 H (H-8); 7.18 m, 20 H (Ar); 6.47 s, 2 H (NH2); 4.52 t, 1 H, J = 11.6 (NH); 
4.21 t, 1 H, J = 11.0 (NH); 3.96 m, 10 H (H-1', Et); 3.79 m, 4 H, (NHCH); 2.84 m, 6 H and 
2.77 m, 2 H (CH2Ph); 2.41 m, 4 H (H-3', H-5’); 1.40 m, 4 H (H-4', H-6'); 1.10 t, 6 H and 1.04 
t, 6 H, J = 7.2 (Et). 
13
C NMR (DMSO-d6): 173.04, 173.02, 172.89 and 172.85 (CO); 156.72 
(C-6); 153.36 (C-2); 150.97 (C-4); 137.38 (C-8); 137.12, 2 C, 137.04, 2 C 129.27, 4 C, 
129.22, 4 C, 127.99, 4 C, 127.95, 4 C, 126.36, 2 C and 126.29, 2 C (Ar); 116.30 (C-5); 60.21 
and 60.12, 4 C (Et); 53.98 m, 4 C (NHCH); 51.46 (C-2’); 46.26 (C-3' and C-5'); 40.00 (C-1'); 
25.64 d, J(P,C) = 113.61 (C-4’ and C-6'); 13.80 m, 4 C (Et). HRMS calcd. for 
C55H73N10O11P2: 1111.49300; found: 1111.49303. MS (ESI): m/z = 1111.5 [M+H]
+
. 
 
Determination of Ki values 
The K
i
 values were determined using a spectrophotometric assay at 25
o
C, 0.1 M Tris-HCl, 10 
mM MgCl
2
, pH 7.4 with PRib-PP as the variable substrate and guanine as the fixed 
substrate.
15 
The K
i 
values are K
i(app) 
as they were measured at a single concentration of the 
second substrate. The concentration of the second substrate (guanine) was saturating: 60 M.  
K
i(app)
 was calculated using the equation  K
m(app)
 = K
m 
(1+ [I]/K
i(app)
). 
 
Evaluation of in vitro antimalarial activity of aza-ANP prodrugs 
P. falciparum D6 (Sierra-Leone) laboratory line, sensitive to most antimalarial drugs and W2 
(Indochina) line, resistant to chloroquine and pyrimethamine, were maintained in RPMI-
1640-LPLF complete medium, containing 10% human plasma, at 4% haematocrit and 1% to 
8% parasitaemia as previously described.
26
 Cultures were routinely synchronised using D-
sorbitol.
27
 To evaluate the antimalarial activity of the ANPs, the [
3
H]-hypoxanthine growth 
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inhibition assay
28
 was utilized, where the uptake of [
3
H]-hypoxanthine by malaria parasites is 
used as a surrogate marker for parasite growth. For these assays, stock solutions of ANPs 
were made to concentrations of 20-40 mM in DMSO or water and subsequently diluted in 
hypoxanthine-free complete media prior to assay. The assays (in 96-well plate format) were 
initiated when the majority of parasites (>90%) at early trophozoite (ring) stage. Parasite 
cultures (100 μL per well) at 0.5% initial parasitemia and 2% hematocrit in hypoxanthine-free 
RPMI1640-LPLF medium were exposed to ten 2-fold serial dilutions of the ANPs and 
chloroquine (CQ) (reference drug) for 96 hours, with [
3
H]-hypoxanthine (0.2 μCi/well) added 
~48 hours after beginning of the experiment. The [
3
H]-hypoxanthine incorporation data were 
analyzed and sigmoidal growth inhibition curves were produced by non-linear regression 
analysis of the [
3
H]-hypoxanthine incorporation data versus log-transformed concentrations of 
the compounds using Graphpad Prism V5.0 software (GraphPad Software Inc. USA), from 
which the inhibitory concentration (IC50) that cause 50% of parasite growth were determined. 
The IC50 values were based on at least two independent experiments with mean  SD 
calculated. 
 
Cytotoxicity assays in human cell lines 
The inhibitory effect of the test compounds on cell proliferation was determined in three 
human cell lines (purchased from the American Type Culture Collection): A549 lung 
carcinoma cells; C32 melanoma cells, and C32-TG mutant cells, which were selected under 6-
thioguanine and are deficient in HGPRT activity due to an exon 2 deletion.
25
 To determine the 
cytostatic effect of the test compounds, the cells were seeded in 96-well plates at 7,500 
(A549) or 15,000 (C32 and C32-TG) cells per well and, 24 hours later, the compounds were 
added at serial dilutions. After four days incubation at 37°C, the cells were trypsinized and 
counted with a Coulter Counter apparatus. The CC50 values, or compound concentrations at 
which cell proliferation was 50% compared to that in untreated cells, were calculated by 
extrapolation. Data presented are the mean ± SEM of two or three independent tests.  
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